Buserelin
Title: Buserelin
CAS Registry Number: 57982-77-1
CAS Name: 6-[O-(1,1-dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamideluteinizing hormone-releasing factor (pig)
Molecular Formula: C60H86N16O13
Molecular Weight: 1239.42
Percent Composition: C 58.14%, H 6.99%, N 18.08%, O 16.78%
Literature References: Synthetic nonapeptide agonist analog of LH-RH, q.v. Synthesis: W. Konig et al., DE 2438350; eidem, US 4024248 (1976, 1977 both to Hoechst); A. S. Dutta et al., J. Med. Chem. 21, 1018 (1978). Clinical pharmacology: A. Lemay et al., Fertil. Steril. 37, 193 (1982). Radioimmunoassay in plasma and urine: S. Saito et al., J. Immunol. Methods 79, 173 (1985). Veterinary use to increase conception rate: K. Moller, E. D. Fielden, N. Z. Vet. J. 29, 214 (1981). Clinical evaluation in prostatic carcinoma: J. H. Waxman, Br. J. Urol. 55, 737 (1983); as ovulatory stimulant for in vitro fertilization: V. MacLachlan et al., N. Engl. J. Med. 320, 1233 (1989). Review of pharmacokinetics and clinical profile: R. N. Brogden et al., Drugs 39, 399-437 (1990); of efficacy in prostatic carcinoma: H. J. de Voogt et al., Scand. J. Urol. Nephrol. Suppl 138, 131-136 (1991).
Properties: [a]D20 -40.4° (c = 1 in dimethylacetamide).
Optical Rotation: [a]D20 -40.4° (c = 1 in dimethylacetamide)
 
Derivative Type: Monoacetate
CAS Registry Number: 68630-75-1
Manufacturers' Codes: HOE-766
Trademarks: Receptal (Intervet); Suprecur (Sanofi-Aventis); Suprefact (Sanofi-Aventis)
Molecular Formula: C60H86N16O13.C2H4O2
Molecular Weight: 1299.48
Percent Composition: C 57.30%, H 6.98%, N 17.25%, O 18.47%
 
Therap-Cat: Antineoplastic (hormonal). Gonad-stimulating principle.
Therap-Cat-Vet: Gonad-stimulating principle.
Keywords: Antineoplastic (Hormonal); LH-RH Analogs; Gonad-Stimulating Principle; LH-RH Agonist.

Others monographs:
KurcholessineGlycocyaminePeanut OilTolfenamic Acid
TOACMetizolineSulfaquinoxalineMethylenedigallic Acid
Algestone2,4-DiiodoanilineFerrous FumarateMoprolol
ProgesteroneVanadium TrifluorideDiazoacetic EsterTocol
©2016 DrugLead US FDA&EMEA